Swedish Orphan Biovitrum AB's (publ) (Sobi) partner Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Commission has approved Cometriq® (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC). The European Commission granted conditional marketing authorisation following a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) issued in December 2013. Similar to another drug approved in this setting, the approved indication states that for patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decisions. "We're pleased that physicians in the European Union who treat patients with progressive, unresectable locally advanced or metastatic MTC now have a new treatment option in Cometriq," said Anders Edvell, MD, PhD, Vice President Sobi Partner Products. The Committee for Orphan Medicinal Products (COMP) also reviewed the designation for Cometriq (cabozantinib) as an orphan medicinal product for the treatment of MTC, and recommended maintenance of orphan drug designation at the time of marketing authorisation. The U.S. Food and Drug Administration approved Cometriq for the treatment of progressive, metastatic MTC in the United States on November 29, 2012. The approvals of Cometriq in both the United States and the European Union were based on data from EXAM, the international, multi-centre, randomised double- blinded controlled phase 3 clinical trial conducted in 330 patients with progressive, unresectable locally advanced or metastatic MTC, in which cabozantinib met its primary efficacy endpoint of improving progression-free survival (PFS) as compared to placebo. Pursuant to the terms of a commercialization and distribution agreement between Exelixis and Sobi signed in February 2013, Sobi will support the commercialisation of Cometriq in the European Union for the approved indication through the end of 2015. --- About Cabozantinib Cabozantinib inhibits the activity of tyrosine kinases including RET, MET and VEGFRs. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with three late stage biological development projects within Haemophilia and Neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. About Sobi Partner Products Sobi Partner Products (SPP) is a business unit within Sobi which offers a unique commercial platform for partners with niche and specialty products. SPP provides extensive knowledge and local experience through our direct presence across EU, Eastern Europe, Russia, Middle East and North Africa. We apply an integrated commercial, medical, and market access approach to products which address important unmet needs, spanning from named patient use (NPU) programs, through to reimbursement and full commercialization, primarily in the Centre of Expertise setting. For more information please contact Media relations Investor relations Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor Communications Relations T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 oskar.bosson@sobi.com jorgen.winroth@sobi.com [HUG#1771497]
Cometriq® approved in Europe for the treatment of
Top 10 Most Recent News Articles
PropWallet: A Game Changer for Prop Firm Payouts?
Change is Brewing in Boca Raton Well, folks, looks like PropAccount.com is shaking up the payout game with their latest brainchild, PropWallet. Launched on November 4, 2026, in sunny Boca Raton, they're setting the stage for a new way to handle payouts at prop trading firms. It's more than just another payout method; it's a ploy for keeping traders hooked and firms...
Continue Reading
Strategies for Maintaining Water Quality in NH Homes
Protect Your Water: Steps to Safe Drinking Imagine turning on your kitchen tap, and instead of refreshing, clean water, you get a murky mystery. Not exactly anyone's dream scenario, right? Enter Sean McGorry and his down-to-earth guide to water quality for New Hampshire homesteaders. It's not rocket science, but the whispers of neglected water systems tell tales of...
Continue Reading
Admetec Shines Bright with New High-Magnification Headlights
Admetec's Leap into Advanced Optical Solutions In the world of optical magnification, getting the right balance of visibility and comfort hasn't always been a straightforward journey. Now, Admetec, coming out of Haifa, Israel, is throwing a game-changer into the mix with their announcement of the Butterfly EVO+ and Orchid+ series. These ain't just any old headlights;...
Continue Reading
Infotech's 2026 Report Crowns PSA Software Leaders
Spotlight on PSA Trailblazers It's 2026, and Infotech has dropped its latest bombshell—the Professional Services Automation Data Quadrant Report. This ain't just your run-of-the-mill software rankings; it's a peek into tools that could make or break project management for service-oriented businesses. Five top dogs, RocketLane, Wrike, Accelo, SAP Professional Services...
Continue Reading
Coronation Securities: Pioneering Digital Brokerage in Nigeria
Coronation Securities: A Digital Revolution Ah, Nigerian financial markets have found themselves a trailblazer, folks. Meet Coronation Securities Limited, recently crowned the 'Fastest Growing Digital Brokerage Platform – Nigeria' at the 2026 Global Brand Awards. Now, that's a nod from Global Brands Magazine worth sitting up for. Turning the Tide with Tech In an...
Continue Reading
Asper.ai's Big Move: Grows Europe Footprint in RGM
Asper.ai Eyes RGM Market with Strategic Acquisition Folks, Asper.ai's latest move is a bold stride into a crowded field, snatching up the expertise of Pricing One to fuel its revenue growth management (RGM) platform. Now, if you're scratching your head over what all this entails, picture it this way: it's like arming a seasoned sales team with cutting-edge tech. This...
Continue Reading
Denison Mines' Q3 2026: Construction and Results Unveiled
Progress at Phoenix ISR Uranium Mine The numbers out from Denison Mines Corp. have got me feeling a mix of cautious optimism and worn-out fatigue, like spotting a $20 bill on a busy street. Their latest earnings release for Q3 2026 carries quite the story — beyond just spreadsheets. The highlight, of course, is the Phoenix ISR uranium mine where they're making tracks...
Continue Reading
Qfin Faces Stock Lawsuit: Know Your Investor Rights
Qfin in the Legal Hot Seat When you hear about a company's legal wranglings, especially one like Qfin Holdings, Inc., you've got to sit up and take notice. We're not talking about a quick scuffle here; this is a full-blown class action lawsuit with its talons sunk deep into allegations of securities law violations. They're squared off against DJS Law Group, an outfit that...
Continue Reading
AlphaESS Secures Fifth Tier 1 Status Amid Growth
AlphaESS: Consistency Breeds Success Can't ignore a company that keeps hitting the marks quarter after quarter, kid. AlphaESS just bagged its fifth consecutive Tier 1 status from BloombergNEF for Q4 2026—that's no joke in the buzzing world of energy storage. What makes this outfit tick? It's not just sticking to the same old script; they keep leveling up while everyone...
Continue Reading
Borussia Dortmund's Q1 2026/2027 Earnings Slip Amid Challenges
An Uneven Start to Borussia Dortmund's Financial Year Every finance year kickoff has its tales, and Borussia Dortmund's start for 2026/2027 is no different. The embattled team has been juggling a mixed bag of financial outcomes, darting through initial challenges with a revenue that hovers slightly above the previous year's mark. Revenue crept up to EUR 107.4 million,...
Continue ReadingTop 5 Most Recently Viewed Articles
Pullman Hotels & Resorts Launches Innovative Brand Revamp
Pullman Hotels & Resorts Introduces a Bold New Identity Pullman Hotels & Resorts is excited to announce a comprehensive transformation of its brand, positioning its hotels not just as places to stay, but as dynamic hubs of creativity and collaboration. This initiative marks a significant milestone for the brand, aiming to attract a new generation of travelers seeking...
Continue Reading
Beko Reinforces Commitment to Energy Efficiency This Earth Day
Beko Reinforces Commitment to Energy Efficiency This Earth Day Celebrating Earth Day's 'Our Power, Our Planet' theme with technology that makes energy efficiency accessible in everyday life As the global community rallies for renewable energy under the theme 'Our Power, Our Planet,' Beko, Europe's leading home appliance manufacturer, is highlighting its dedication to...
Continue Reading
United States Oil Fund Shares Monthly Financial Insights
The United States Oil Fund, LP (NYSE: USO) reported significant financial performance back in 2024 that made traders sit up and take notice. The numbers were big—revenue growth soared by over 188% year-on-year, showing just how much demand for crude oil was pushing this commodity ETF into the spotlight. You had desks buzzing about this upward trajectory while trying to...
Continue Reading
Military Grade Cases Market Poised for Major Expansion
Growth of the Military Grade Cases Market The military grade cases market is on a continuous upward trajectory, with estimates projecting its market size to be around USD 390.3 million. Despite previous revenues of USD 371.7 million, the market is set to expand significantly, reaching an anticipated value of USD 552.1 million by 2034, representing a cumulative annual...
Continue Reading
SoftwareOne Unveils Advanced GenAI Cost Optimization System
SoftwareOne Launches Innovative GenAI Multi-Agent System SoftwareOne has introduced an advanced GenAI multi-agent cost optimization system that assists clients in managing and refining the costs and performance of their AI agents. This new offering stems from their extensive experience in both AI technologies and software asset management, positioning the company to help...
Continue Reading